CriticalNatural opium alkaloids×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative
Updated · Methodology
Mechanism
Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO), the enzyme that breaks down serotonin, noradrenaline and dopamine (tranylcypromine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). According to the US morphine label, MAO inhibitors may potentiate the effects of morphine, including respiratory depression, coma and confusion, and their interactions with opioids may present as serotonin syndrome or opioid toxicity (morphine label, US Food and Drug Administration, FDA, sections 5.8 and 7). The Spanish tranylcypromine SmPC warns that the effect of central nervous system depressants, analgesics included, may increase during combined use (tranylcypromine SmPC, AEMPS, section 4.5). The US tranylcypromine label names the same consequence for opioids: increased central nervous system depression (tranylcypromine FDA label, section 7.1).
Symptoms
The documents do not say how this particular combination presents: they contraindicate it pre-emptively. The US morphine label warns of respiratory depression, confusion and coma (morphine label, US Food and Drug Administration, FDA, section 5.8) or serotonin syndrome (FDA morphine label, section 7). Respiratory depression is most likely when morphine is started or the dose is increased, and without prompt treatment it may lead to respiratory arrest and death (FDA morphine label, section 5.2). Serotonin syndrome presents with mental status changes (agitation, hallucinations, delirium, coma), autonomic instability (fast heart rate, labile blood pressure, dizziness, sweating, flushing, high temperature), neuromuscular symptoms (tremor, rigidity, myoclonus, exaggerated reflexes, poor coordination), seizures, nausea, vomiting and diarrhoea, and it can be fatal (tranylcypromine FDA label, section 5.3).
Management
The combination is contraindicated. Spanish summaries of product characteristics (SmPCs) for oral morphine contraindicate morphine with monoamine oxidase (MAO) inhibitors and within two weeks of stopping them (morphine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.3), and tranylcypromine inhibits MAO according to its own SmPC (tranylcypromine SmPC, AEMPS, section 5.1). The US morphine label sets the same 14-day ban and names tranylcypromine among the examples (morphine label, US Food and Drug Administration, FDA, sections 4 and 7). Start morphine no earlier than two weeks after stopping tranylcypromine (morphine SmPC, AEMPS, section 4.3; FDA morphine label, sections 4 and 5.8), and do not start an MAO inhibitor while the patient is taking morphine (FDA morphine label, section 17). The Spanish SmPC for injectable morphine is milder: it advises using MAO inhibitors with morphine with caution and at a reduced dose (injectable morphine SmPC, AEMPS, section 4.5). The tranylcypromine documents do not name morphine and advise caution with central nervous system depressants, opioids included (tranylcypromine FDA label, section 7.1). Before planned surgery with anaesthetics or certain analgesics, consider stopping tranylcypromine 14 days in advance (tranylcypromine SmPC, AEMPS, section 4.5); the US label recommends stopping it at least 10 days before elective surgery (tranylcypromine FDA label, section 5.6). If signs of serotonin syndrome appear, stop tranylcypromine and any concomitant serotonergic drugs at once and start supportive symptomatic treatment (tranylcypromine FDA label, section 5.3).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Morfina Serra 10 mg/ml solución inyectable (nº registro 37473), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 37473, revisión 09/2026, secciones 4.4 y 4.5
- FDA: MS Contin (morphine sulfate) prescribing information (2026)– FDA, DailyMed setid c354b3bf-86c0-4bb8-8b1f-be2164942698 (Rhodes Pharmaceuticals), version 18, revised 08/2026, Boxed Warning, sections 4, 5.3, 5.8 and 7
- AEMPS: Ficha técnica: Morfina, MST Continus 10 mg (nº registro 57898) (2025)– AEMPS, CIMA, nº registro 57898 (MST Continus 10 mg comprimidos de liberación prolongada), revisión 03/2025, secciones 4.3, 4.4 y 4.5
- FDA: Parnate (tranylcypromine) prescribing information (2025)– FDA, DailyMed, Advanz Pharma, setid b72d8187-dfcc-4ea0-b5e9-c0be95b69a27, revised 07/2025, sections 4.1, 5.3, 5.9 and 7.1
- AEMPS: Ficha técnica: Tranilcipromina (nº registro 88524), sección 4.5 (2026)– AEMPS, CIMA, nº registro 88524 (Tranilcipromina Aristo 20 mg comprimidos recubiertos con película; autorizado, no comercializado), revisión 08/2026 (texto revisado 04/2026), secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.1